权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Anti-Epileptic Action of ABHD6 Inhibitors as Treatment for Dravet Syndrome

ABHD6 抑制剂治疗 Dravet 综合征的抗癫痫作用

基本信息

批准号：
9331065
负责人：
Nephi Stella
金额：
$ 23.23万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-04-01 至 2019-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9331065
关键词：
2-arachidonylglycerol 2-arachidonylglycerol signaling ABHD6 gene Action Potentials Address Adverse effects Affect Antiepileptic Agents Applications Grants Bathing Behavioral Biological Models Brain CNR1 gene CNR2 gene Cessation of life Characteristics Child Clonic Seizure Data Dose Electroencephalogram Electrophysiology (science)Endocannabinoids Environment Enzymes Epilepsy Exhibits Fever Foundations Frequencies Genetic Grant Hippocampus (Brain)Human Hydrolase Incidence Intractable Epilepsy Knockout Mice Measurement Measures Modeling Molecular Molecular Mechanisms of Action Monitor Mus Myoclonic Epilepsies Organ Outcome Pentylenetetrazole Pharmaceutical Preparations Picrotoxin Predisposition Pump Regimen Reporting Research Seizures Severities Slice Solid Stimulus Synaptic Transmission Syndrome Temperature Testing Therapeutic Tonic Seizures Toxic effect Treatment Efficacy Work base cannabinoid receptor design experimental study follow-up in vivo infancy inhibitor/antagonist mouse model mutant mouse model neuronal excitability novel novel therapeutic intervention novel therapeutics postnatal postsynaptic pre-clinical premature prevent receptor response therapeutic evaluation treatment response treatment strategy

项目摘要

Summary The newly discovered enzyme, α/β-hydrolase domain 6 (ABHD6), controls the amount of 2- arachidonoylglycerol (2-AG), the most abundant endocannabinoid (eCB) in the brain. We recently found that in vivo ABHD6 inhibition decreases seizure incidence in several mouse models of epilepsy, and that this therapeutic response does not undergo tolerance nor does it produce overt side effects. These results suggest that ABHD6 inhibition might represent a novel anti-epileptic therapeutic approach. In this R21 grant proposal, we will test the therapeutic efficacy of a novel inhibitor of ABHD6, KT-182, in Scn1a+/- mice, a preclinical mouse model of Dravet Syndrome that accurately mimics this devastating intractable epilepsy that begins in infancy. Our hypothesis is that ABHD6 inhibition will significantly reduce seizure severity in Scn1a+/- mice without producing overt side effect and tolerance. To test this hypothesis, we will address three aims: 1. Effect of ABHD6 inhibition on thermally-induced seizures 2. Effect of ABHD6 inhibition on spontaneous seizures and premature death 3. Effect of ABHD6 inhibition on EEG and neuronal excitability The results gathered through this R21 grant will provide a solid foundation for future research aimed at developing ABHD6 inhibitors as new therapeutics for the treatment of Dravet Syndrome. This research will also increase our basic understanding of the molecular mechanisms by which endogenous 2-AG signalling controls synaptic transmission and seizure incidence.

总结新发现的酶，α/β-水解酶结构域6（ABHD 6），控制2- 花生四烯酰甘油（2-AG），大脑中最丰富的内源性大麻素（eCB）。我们最近发现，体内ABHD 6抑制降低了几种癫痫小鼠模型中的癫痫发作发生率，治疗反应不会产生耐受性，也不会产生明显的副作用。这些结果提示ABHD 6抑制可能代表一种新抗癫痫治疗方法。在这项R21资助提案中，我们将测试一种新型ABHD 6抑制剂KT-182的治疗功效 Scn 1a +/-小鼠，Dravet综合征的临床前小鼠模型，准确地模拟了这种破坏性的从婴儿期开始的顽固性癫痫。我们的假设是ABHD 6抑制将显著降低 Scn 1a +/-小鼠癫痫发作严重程度，而不产生明显的副作用和耐受性。为了验证这个假设，我们将实现三个目标： 1. ABHD 6抑制对热诱导癫痫发作的影响 2. ABHD 6抑制对自发性癫痫发作和过早死亡的影响 3. ABHD 6抑制对EEG和神经元兴奋性的影响通过R21资助收集的结果将为未来的研究提供坚实的基础，旨在开发ABHD 6抑制剂作为治疗Dravet综合征的新疗法。这项研究将也增加了我们对内源性2-AG信号传导的分子机制的基本理解，控制突触传递和癫痫发作率。